Precision BioSciences, Inc. (DTIL)

Over the past six months, Precision BioSciences' stock price has experienced a general falling trend. As of January 30, 2026, the share price was $3.96, a decline of 15.20% from $4.67 on February 3, 2025. The stock's 52-week range has been between $3.53 and $8.82. Recent trading days in late January and early February 2026 showed daily fluctuations, with prices ranging from approximately $3.73 to $4.61. On February 5, 2026, the stock closed at $3.57, and a buy signal was issued from a pivot bottom point on the same day. The stock holds sell signals from both short and long-term Moving Averages, indicating a negative forecast in the near term. On January 13, 2026, Precision BioSciences outlined its 2026 strategic priorities, focusing on advancing its lead ARCUS-based in vivo gene editing programs, PBGENE-HBV and PBGENE-DMD. Insider selling activity by various executives and directors was observed in late 2025 and early 2026.

The demand for Precision BioSciences' products and services is primarily driven by medical need, clinical trial progress, and regulatory approvals, rather than typical consumer-driven seasonal patterns. The nature of its business suggests that demand would be relatively consistent once a therapy is approved and marketed, independent of calendar seasons.

Precision BioSciences, Inc. is a clinical-stage biotechnology company focused on improving life through its proprietary ARCUS® genome editing platform. The company operates within the medical sector, specifically the biotechnology industry, and specializes in developing in vivo gene editing therapies for gene insertion, excision, and elimination. The company's core technology is the ARCUS genome editing platform, designed for therapeutic safety, delivery, and control. Using ARCUS, the company is developing therapies for various conditions, including in vivo gene correction therapies for cancer and infectious diseases. Its major product pipeline candidates include PBGENE-HBV for chronic hepatitis B virus, PBGENE-3243 for m.3243 associated mitochondrial myopathy (development paused), PBGENE-NVS (insertion) with Novartis Pharma AG for hemoglobinopathies, PBGENE-DMD (excision) for Duchenne muscular dystrophy, PBGENE-LIVER (insertion) for a liver-directed target, PBGENE-CNS (excision) for a central nervous system-directed target, and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company also has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer.

Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. It maintains additional research and manufacturing capabilities in the Research Triangle Park area. The company primarily develops therapeutic products in the United States.

Precision BioSciences' brand reputation in the past year has been impacted by financial challenges, including a negative revenue growth rate of -44.65% in the trailing twelve months (TTM) and significant losses, with a net profit margin of -119.77% and an EBIT margin of -87.0%. The company has also faced a decline in revenue due to the conclusion of collaborative agreements, such as the Prevail/Lilly partnership. Despite these financial hurdles, the company's focus on its proprietary ARCUS platform for gene editing and its pipeline development for serious diseases like chronic hepatitis B and Duchenne muscular dystrophy contribute to its scientific reputation. Analyst ratings for DTIL show a consensus of "Hold" based on two reports, with one "Buy" and one "Sell" rating. Another analysis indicates a "Strong Buy" consensus from one analyst. The company's MarketRank™ score suggests it performs better than 52% of companies evaluated by MarketBeat in the medical sector.

Precision BioSciences, Inc. has 80 institutional owners and shareholders holding a total of 7,384,132 shares. Major institutional owners include Standard Life Aberdeen plc, Bleichroeder LP, Lynx1 Capital Management LP, Vanguard Group Inc, Tang Capital Management Llc, Vanguard Extended Market Index Fund Investor Shares (VEXMX), Renaissance Technologies Llc, Boothbay Fund Management, Llc, Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), and Acadian Asset Management Llc. Individual insider owners include J Jefferson Smith, John Alexander Kelly, Geno J Germano, Melinda Brown, Stanley Frankel, Dario Scimeca, and Alan List.